Real-world treatment patterns and healthcare costs in patients with psoriasis taking systemic oral or biologic therapies.

This study identified lower persistence in the oral treatment cohort, higher costs associated with switching, and a need for safe and effective oral options for patients with psoriasis to delay the switch to biologic therapy.